NEW YORK (GenomeWeb) — OncoSec Medical, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it is working with the University of California, Los Angeles and PerkinElmer to develop molecular biomarkers to measure patients' immune responses to cancer.

OncoSeq said that the effort will use PerkinElmer’s imaging-based staining methods to quantitatively evaluate CD8+ T cell density, with the goal of developing markers that can distinguish responders from non-responders to anti-PD-1 monotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.